Bylund S, von Kobyletzki LB, Svalstedt M, Svensson Å. Prevalence and incidence of atopic dermatitis: a systematic review. Acta Derm Venereol. 2020;100(12):adv00160.

Article  PubMed  Google Scholar 

Davis DMR, Drucker AM, Alikhan A, Bercovitch L, Cohen DE, Darr JM, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024;90(2):e43-56.

Article  CAS  PubMed  Google Scholar 

Wollenberg A, Kinberger M, Arents B, Aszodi N, Avila Valle G, Barbarot S, et al. European guideline (EuroGuiDerm) on atopic eczema: part I–systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409–31.

Article  CAS  PubMed  Google Scholar 

Bieber T. Interleukin-13: targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75(1):54–62.

Article  CAS  PubMed  Google Scholar 

Tsoi LC, Rodriguez E, Degenhardt F, Baurecht H, Wehkamp U, Volks N, et al. Atopic dermatitis is an IL-13-dominant disease with greater molecular heterogeneity compared to psoriasis. J Investig Dermatol. 2019;139(7):1480–9.

Article  CAS  PubMed  Google Scholar 

David E, Ungar B, Renert-Yuval Y, Facheris P, Del Duca E, Guttman-Yassky E. The evolving landscape of biologic therapies for atopic dermatitis: present and future perspective. Clin Exp Allergy. 2023;53(2):156–72.

Article  CAS  PubMed  Google Scholar 

Lovell K, Patel N, Rao S, Strowd LC. The future of atopic dermatitis treatment. Adv Exp Med Biol. 2024. https://doi.org/10.1007/978-3-031-54513-9_19.

Article  PubMed  Google Scholar 

Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130–9.

Article  PubMed  Google Scholar 

Halling AS, Loft N, Silverberg JI, Guttman-Yassky E, Thyssen JP. Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J Am Acad Dermatol. 2021;84(1):139–47.

Article  CAS  PubMed  Google Scholar 

Vittrup I, Krogh NS, Larsen HHP, Elberling J, Skov L, Ibler KS, et al. A nationwide 104 weeks real-world study of dupilumab in adults with atopic dermatitis: ineffectiveness in head-and-neck dermatitis. J Eur Acad Dermatol Venereol. 2023;37(5):1046–55.

Article  CAS  PubMed  Google Scholar 

Willsmore ZN, Woolf RT, Hughes C, Menon B, Kirkham B, Smith CH, et al. Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series. Br J Dermatol. 2019;181(5):1068–70.

Article  CAS  PubMed  Google Scholar 

Jay R, Rodger J, Zirwas M. Review of dupilumab-associated inflammatory arthritis: an approach to clinical analysis and management. JAAD Case Rep. 2022;21:14–8.

Article  PubMed  PubMed Central  Google Scholar 

Simpson EL, Merola JF, Silverberg JI, Reich K, Warren RB, Staumont-Sallé D, et al. Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials. Br J Dermatol. 2022;187(6):888–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wollenberg A, Beck LA, de Bruin WM, Simpson EL, Imafuku S, Boguniewicz M, et al. Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials. Br J Dermatol. 2022;186(3):453–65.

Article  CAS  PubMed  Google Scholar 

Silverberg JI, Hong HC, Thyssen JP, Calimlim BM, Joshi A, Teixeira HD, et al. Comparative efficacy of targeted systemic therapies for moderate to severe atopic dermatitis without topical corticosteroids: systematic review and network meta-analysis. Dermatol Ther (Heidelb). 2022;12(5):1181–96.

Article  PubMed  PubMed Central  Google Scholar 

Bissonnette R, Eichenfield LF, Simpson E, Thaçi D, Kabashima K, Thyssen JP, et al. Estimands for atopic dermatitis clinical trials: expert opinion on the importance of intercurrent events. J Eur Acad Dermatol Venereol. 2023;37(5):976–83.

Article  CAS  PubMed  Google Scholar 

Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021;157(9):1047–55.

Article  PubMed  PubMed Central  Google Scholar 

Reich K, Thyssen JP, Blauvelt A, Eyerich K, Soong W, Rice ZP, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Lancet. 2022;400(10348):273–82.

Article  CAS  PubMed  Google Scholar 

Bieber T, Simpson EL, Silverberg JI, Thaçi D, Paul C, Pink AE, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021;384(12):1101–12.

Article  CAS  PubMed  Google Scholar 

Chiricozzi A, Ferrucci SM, Di Nardo L, Gori N, Balato A, Ortoncelli M, et al. Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study. Expert Opin Biol Ther. 2023;23(12):1307–15.

Article  CAS  PubMed  Google Scholar 

Pezzolo E, Schena D, Gambardella A, Rossi M, Barei F, Calzavara Pinton P, et al. Survival, efficacy and safety of tralokinumab after 32 and 52 weeks of treatment for moderate-to-severe atopic dermatitis in adults: a multicentre real-world study. J Eur Acad Dermatol Venereol. 2024;38(1):11–3.

Article  Google Scholar 

Lio P, Kim Y, Balu S, Costantino H, Bates D, Rene C, et al. Tralokinumab real-world patient-reported outcomes in moderate-to-severe atopic dermatitis adult patients in the United States: 6-month interim analysis. Skin. 2024;8(1): s318.

Article  Google Scholar 

NHLBI. Study quality assessment tools. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools. Accessed 22 Sept 2024.

Caroppo F, Belloni FA. Real-life case-series experience with tralokinumab in patients with severe atopic dermatitis. JEADV Clin Pract. 2024;3(1):296–300.

Article  Google Scholar 

García Castro R, Heras Mendaza F, Santiago Sánchez-Mateos DI, Fariña Sabrís MC, Alcaraz LI. First short-term effectiveness and security data of tralokinumab in severe atopic dermatitis in real clinical practice. Dermatitis. 2024;35(3):301–3.

Article  PubMed  Google Scholar 

Gargiulo L, Ibba L, Vignoli CA, Facheris P, Valenti M, Costanzo A, et al. Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: a real-life 16-week experience. J Dermatol Treat. 2023;34(1):2216815.

Article  Google Scholar 

Licata G, Tancredi V, Pezzolo E, Pertusi G, Tolino E, Arisi M, et al. Efficacy and safeness of tralokinumab in patients with atopic dermatitis who developed conjunctivitis under dupilumab: a case series. J Eur Acad Dermatol Venereol. 2023;37(8):e1064–5.

Article  Google Scholar 

Pezzolo E, Naldi L. Tralokinumab in the treatment of resistant atopic dermatitis: an open-label, retrospective case series study. J Eur Acad Dermatol Venereol. 2023;37(5):e644–5.

Article  CAS  PubMed  Google Scholar 

De Greef A, Ghislain PD, de Montjoye L, Adriaenssens K, Bulinckx A, Colmant C, et al. Tralokinumab improves clinical scores in adolescents with severe atopic dermatitis: a real-life multicentric observational study. J Eur Acad Dermatol Venereol. 2024;38(3):e288–90.

PubMed  Google Scholar 

Herman EI, Burgy J, Shahriari M. A retrospective multicenter case series of real-world tralokinumab use in dupilumab-experienced patients. JAAD Case Rep. 2024;46:40.

Article  PubMed  PubMed Central  Google Scholar 

Martora F, Patruno C, D’Ascenzo S, Napolitano M. Injection site reactions after dupilumab or tralokinumab for atopic dermatitis. J Dermatol Treat. 2024;35(1):2304027.

Article  Google Scholar 

Musters AH, van Lookeren FL, van der Gang LF, Middelkamp-Hup MA, Bosma AL, Jessurun NT, et al. Real-world reported adverse events related to systemic immunomodulating therapy in patients with atopic dermatitis: results from the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry. J Eur Acad Dermatol Venereol. 2024;38(3):530–42.

Article  CAS  PubMed  Google Scholar 

Gori N, Ippoliti E, Ferrucci SM, Balato A, Ortoncelli M, Maurelli M, et al. Successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: a case series. J Eur Acad Dermatol Venereol. 2024;38(10):e852–4.

Article